Lastly, it is important to note that the ctDNA concentrations in plasma are dependent on tumor burden, site of metastasis but also genotype and EGFR gene amplifications which might impair performance of the EGFR mutation detection form plasma (Lam et al., 2020). The gene discussed is EGFR; the disease is neoplasm.